Evolving Treatment Paradigms in NDMM : Episode 3
Anti-CD38 Quadruplet Induction Regimens in TE NDMM: New Standard of Care
Panelists discuss how while daratumumab-based quadruplet regimens are increasingly becoming the standard of care for patients with transplant-eligible newly diagnosed multiple myeloma (TE NDMM) due to superior efficacy data, certain factors like frailty, comorbidities, and cost considerations may still warrant triplet therapy in select cases.
Video content above is prompted by the following:
- From your experience, do you believe that daratumumab-based quadruplet induction regimens are the new standard of care for TE NDMM patients?
- In which patients would you consider induction with a triplet regimen?
Recent Videos
Related Content
Fostering Academic, Community Practice Collaboration for Bispecific Therapy in Multiple Myeloma
December 26th 2024Article
Experts in multiple myeloma spoke about optimal treatment strategies for patients who receive bispecific therapy, focusing specifically on facilitating a multifaceted approach between academic and community practices.
